medical

SINGAPORE (Oct 16): Trendlines Medical Singapore, a 76.43%-owned subsidiary of Catalist-listed Israeli company The Trendlines Group, has made its first investment by committing a total of US$60,000 ($81,150) to a medical device start-up, InterVaal.

SINGAPORE (Oct 3): OCBC Investment Research is maintaining its “hold” call on healthcare-focused First REIT with a fair value estimate of $1.38, following the release of Singapore’s latest inflation figures.

Introducing the latest treatments and upgraded technologies at David Loh Surgery

SINGAPORE (Aug 23): UOB Kay Hian is maintaining its “hold” call on media group Singapore Press Holdings (SPH) with a lower target price of $2.85 compared to $2.90, as well as a recommended entry price of $2.60.

SINGAPORE (July 31): Billionaire former stockbroker Peter Lim is on his way to transforming Rowsley into a healthcare company — by injecting into the public-listed company assets that are already familiar to the market.

SINGAPORE (June 5): Maybank Kim Eng Research continues to rate Raffles Medical Group (RMG) at “buy” as Singapore’s leading integrated healthcare provider, with a “robust track record and exciting development plans” of two hospitals in China.

SINGAPORE (June 5): Maybank Kim Eng Research is maintaining its “hold” call on IHH Healthcare with a higher price target of RM6.17 ($2) from RM5.62 previously, highlighting the stock as a healthcare leader in the premium hospital segment with a strong

SINGAPORE (June 2): Singapore’s merger and acquisition (M&A) landscape saw a total of 56 deals worth US$13.8 billion ($19.1 billion) from Jan 2014 to April 2017, based on data compiled by Mergermarket Group, the media company specialising in corporate f

SINGAPORE (May 9): DBS Vickers Securities is maintaining its “buy” rating on Perennial Real Estate holdings with a target price of $1.05, following its strong 1Q17 set of results boosted by gains from its partial divestment of TripleOne Somerset in Ja

SINGAPORE (March 16): In a country where cannabis – commonly also known as marijuana, weed or pot – is recognised as a Class A controlled drug, a bio-technology company is seeking to pursue opportunities in a sector where its medicinal use is legalise